NCT03271541View on ClinicalTrials.gov

A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 26, 2017

Primary Completion Date

June 29, 2018

Study Completion Date

June 29, 2018

Conditions
Beta-Thalassemia
Interventions
DRUG

Bitopertin

Bitopertin will be administered orally once daily at doses up to 120 milligrams (mg).

Trial Locations (4)

1003

Chronic Care Center, Baabda

10700

Siriraj Hospital; Division of Haematology-Oncology, Bangkok Noi

16128

Centro della Microcitemia e delle Anemie Congenite - Ospedale Galliera; Oncologia /Cardiologia, Genoa

20122

Ospedale Maggiore di Milano; Cardio-Metabolic Diseases, Milan

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03271541 - A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia | Biotech Hunter | Biotech Hunter